**Agenus News** will provide our stakeholders and patients with regular updates on our progress and relevant developments in the I–O field that relate to our business, technologies and pipeline.

### 31% of Patients with Refractory Cancers Treated with AGEN1884 (CTLA–4) Had Clinical Benefit¹

In our trial, an angiosarcoma patient, who was refractory to multiple prior therapies, had a complete and durable response to the lowest dose of AGEN1884. The patient remains disease free today, over one year later. You can hear her [story on CBS news](https://www.cbsnews.com/). Other patients with refractory breast cancer, soft tissue sarcoma, and adenoid cystic carcinoma (ACC) treated with AGEN1884 have had clinical benefit (see data presented at ASCO). In light of these responses we have launched our expansion trial for AGEN1884 in PD–1/PD–L1 relapse/refractory patients ([NCT02694822](https://clinicaltrials.gov/ct2/show/NCT02694822)). This trial has the potential to lead to an accelerated approval path.

### 42% of Patients had Clinical Benefit with AGEN2034 (PD–1) in Treatment–Resistant Ovarian, Cervical, Breast Cancer, & Other Tumors²

In our ongoing trial of AGEN2034 (anti–PD–1), we have seen clinical benefit with confirmed partial responses in platinum–resistant ovarian cancer, cervical cancer, and breast cancer. Based on this clinical activity, we have expanded our PD–1 monotherapy trial for patients with refractory cervical cancer ([NCT03104699](https://clinicaltrials.gov/ct2/show/NCT03104699)). Also, 5 out of 5 patients with refractory ovarian cancer had clinical responses. We expect to present updated clinical results on cervical cancer at a conference later this year.
Based on robust response rates to our PD-1 monotherapy trial in gynecological cancers, we initiated our combination study of AGEN1884 and AGEN2034. The trial is in solid tumors including refractory cervical cancer (NCT03495882). We have seen early evidence of clinical activity with the combination in cervical cancer, ovarian and triple-negative breast cancer. We expect to present updated clinical results at a conference later this year.

AgenTus Status Update

Our cell therapy assets are successfully integrated in AgenTus, a subsidiary of Agenus. This was a prerequisite to initiate financing and enable a potential public listing. AgenTus’ pipeline includes T cell receptors (TCR) and Chimeric antigen receptors (CAR) formulated in both autologous and allogeneic cell formats. Our proprietary T-Rx™ platform is empowered to quickly discover and optimize cell therapies. AgenTus’ lead program targeting NYESO1 is planned for the clinic next year. Also, AgenTus was the first to discover and fully characterize a fully human TCR that targets a novel phosphopeptide neoepitope with applications across multiple indications (see the data here). AgenTus discoveries are expanding the range of our therapeutic capabilities and in combination with our checkpoint portfolio, is expected to provide curative therapies.

1 Phase 1 multicenter study to evaluate the safety, PK, and PD of an anti-CTLA-4 human monoclonal antibody (AGEN1884) with expansion cohorts at 1 mg/kg and 3 mg/kg; Reported on first 33 patients enrolled.

2 Phase 1, open-label, dose-escalation trial in subjects with metastatic or locally advanced solid tumors, and Phase 2 expansion to evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum doublet. Reported on first 47 patients enrolled.

Forward-Looking Statements: This news brief contains forward-looking statements regarding Agenus and AgenTus’ that are subject to risks and uncertainties. Please refer to this link for more details.